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Small molecule sensitization to TRAIL is mediated via
nuclear localization, phosphorylation and inhibition
of chaperone activity of Hsp27
G Mellier1,2, D Liu1,3, G Bellot1, A Lisa Holme4,6 and S Pervaiz*,1,2,3,4,5
The small chaperone protein Hsp27 confers resistance to apoptosis, and therefore is an attractive anticancer drug target.
We report here a novel mechanism underlying the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizing
activity of the small molecule LY303511, an inactive analog of the phosphoinositide 3-kinase inhibitor inhibitor LY294002, in
HeLa cells that are refractory to TRAIL-induced apoptosis. On the basis of the fact that LY303511 is derived from LY294002, itself
derived from quercetin, and earlier findings indicating that quercetin and LY294002 affected Hsp27 expression, we investigated
whether LY303511 sensitized cancer cells to TRAIL via a conserved inhibitory effect on Hsp27. We provide evidence that upon
treatment with LY303511, Hsp27 is progressively sequestered in the nucleus, thus reducing its protective effect in the cytosol
during the apoptotic process. LY303511-induced nuclear translocation of Hsp27 is linked to its sustained phosphorylation via
activation of p38 kinase and MAPKAP kinase 2 and the inhibition of PP2A. Furthermore, Hsp27 phosphorylation leads to the
subsequent dissociation of its large oligomers and a decrease in its chaperone activity, thereby further compromising the death
inhibitory activity of Hsp27. Furthermore, genetic manipulation of Hsp27 expression significantly affected the TRAIL sensitizing
activity of LY303511, which corroborated the Hsp27 targeting activity of LY303511. Taken together, these data indicate a novel
mechanism of small molecule sensitization to TRAIL through targeting of Hsp27 functions, rather than its overall expression, leading
to decreased cellular protection, which could have therapeutic implications for overcoming chemotherapy resistance in tumor cells.
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Since its discovery almost two decades ago, tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL) has
garnered heightened interest due to its ability to selectively
induce apoptosis in tumor cells, whereas eliciting minimal
toxicity to normal cells.1–4 However, there is sufficient experi-
mental evidence that a variety of human tumors are intrinsically
resistant to TRAIL-induced apoptosis or could rapidly acquire
a resistant phenotype.5–7 Nevertheless, the promise of a
selective therapeutic agent as well as the growing under-
standing of TRAIL signaling, in particular the focused attention
on the mechanisms responsible for resistance, have triggered
an intense search for novel compounds that are able to restore
tumor cell sensitivity to TRAIL. To that end, a large number of
small molecules have shown promising results, some of which
are already used as mono-therapeutic agents in the clinic (e.g.,
fluorouracil, etoposide and cisplatin).8–10 Previously, we
reported that LY303511 (LY30), an inactive analog of the
phosphoinositide 3-kinase inhibitor (PI3K) LY294002 (LY29),
could strongly enhance tumor cells sensitivity to TRAIL-
mediated apoptosis in a PI3K-independent manner. Although,
these data indicated involvement of reactive oxygen species
(ROS)-mediated mitogen-activated protein kinases (MAPKs)
activation, amplification of the apical TRAIL signal and robust
activation of the intrinsic apoptotic pathway,11,12 our recent
work has focused on identifying underlying resistance mechan-
isms targeted by L30.
Hsp27 is a member of the small heat-shock proteins
(sHsps). Hsp27 is a stress-activated chaperone protein that
displays an abnormal expression in numerous tumor cells and
provides them with an enhanced protection against drug-
induced cell death.13,14 Hsp27 has an important role in
inhibiting both extrinsic and intrinsic cell death pathways by
preventing the translocation of the truncated form of BID to the
mitochondria.15 It also interacts with cytochrome c after its
release from the mitochondria16 and can disrupt caspase-3
activation.17 In addition, Hsp27 possesses an ATP-indepen-
dent chaperone-like activity due to the ability of its large
oligomers to form reservoirs of misfolded proteins during
cellular stresses, thereby attenuating the irreversible and toxic
aggregation of denatured proteins.18
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In this study, we evaluated the effect of LY30 with respect to
Hsp27 survival functions based on our previous work hinting
at a pleiotropic role of this small molecule. We show that LY30,
independently of TRAIL, induced sustained Hsp27 phosphor-
ylation via activation of the p38/MK2 pathway and inhibition of
PP2A, leading to Hsp27 de-oligomerization and nuclear
sequestration as well as impairment of its chaperone activity.
These data shed light on a novel mechanism, independent of
TRAIL apical signaling, by which the small molecule LY30
restores or enhances cancer cells’ sensitivity to TRAIL
treatment.
Results
LY30 restores sensitivity to TRAIL-induced cell death.
First, the variant of human cervical cancer HeLa cell line
used in this study was significantly refractory to long-term
treatment with TRAIL (for up to 72 h), with only 250 ng/ml of
TRAIL for 72 h eliciting a modest effect on cell viability
(Figure 1a). However, as seen in Figure 1b, addition of LY30
restored HeLa sensitivity to TRAIL in a synergistic manner,
corroborating our earlier findings that LY30 sensitized human
tumor cells to TRAIL-induced cell death.11,12 The synergism
between LY30 and TRAIL was assessed by calculating the
combination index (CI) using the Chou-Talalay method
(CI¼ 0.030 for 25 mM of LY30 and 20 ng/ml of TRAIL)
(Figure 1b).19 The same concentrations were used through-
out the rest of the study. Dose-response curves for TRAIL
and LY30 were also established by evaluating the effect of
increasing doses of TRAIL (0, 10 and 20 ng/ml) and LY30
(0–6.25 mM) on cell viability after 16 h (Figure 1c). Interest-
ingly, different doses of TRAIL did not yield significantly
different results, whereas increasing the dose of LY30
significantly decreased cell viability in a dose-dependent
manner up to 3.125 mM when it reached a plateau. This result
shows that the sensitization is highly dependent on LY30
concentration at lower doses, whereas lower doses of TRAIL
are sufficient. As in our earlier reports, the observed cell
death was apoptotic as seen by the dependency on
caspases activation and engagement of the mitochondrial
cell death pathway (Supplementary Figure 1). Interestingly,
the observed sensitization was enhanced in a dose-
dependent manner as a function of TRAIL concentration.
In HeLa cells treated with 25 mM LY30 and 20 ng/ml TRAIL
Figure 1 LY30 restores sensitivity to TRAIL-mediated cell death. (a) Crystal violet viability assay of HeLa cells treated with treated with TRAIL alone (0–250 ng/ml) for 24,
48 or 72 h. (b) CI of LY30 and TRAIL calculated with the Chou-Talalay method. (c) Crystal violet viability assay of HeLa cells treated with TRAIL (0, 10 and 20 ng/ml) for 16 h
with or without 1 h preincubation with various doses of LY30 (0–6.125mM). (d) Crystal violet viability assay of HeLa cells treated with 25 mM of LY30 and 20 ng/ml of TRAIL for
various durations. (e) Trypan blue exclusion assay for HeLa cells treated with 20 ng/ml of TRAIL for 16 h with or without preincubation with 25 mM LY30. (f) Colony-forming
assay for HeLa cells treated with 20 ng/ml of TRAIL for 6 h with or without preincubation with 25 mM LY30 before re-seeding. Colony count and colony size measurements are
also provided. Data shown are the mean±S.D. of three independent experiments. NT: not treated, LY: LY30, T: TRAIL, LYT: LY30þ TRAIL
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alone or in combination, viability was decreased in a time-
dependent manner (Figure 1d). Of note, at 16 h of treatment,
the lower viability readings seen upon treatment with LY30
alone could be attributed to a decrease in cell number rather
than cell death (Figure 1e). In addition to the enhanced
sensitization of HeLa cells to TRAIL by LY30, the two drugs
in combination inhibited the colony-forming ability of the
tumor cells, whereas neither drug used alone had any effect
on tumor colony-forming ability, although TRAIL alone was
able to reduce the size of the colonies (Figure 1f).
Hsp27 silencing/overexpression directly affects cells
sensitivity/resistance to TRAIL. Several studies have
previously shown that both quercetin and LY29 (which is
derived from quercetin) (Supplementary Figure 2) have an
effect on the expression and/or induction of the survival
protein Hsp27.20–23 As LY30 is derived from LY29, we were
interested to see whether artificial modulation of Hsp27
protein expression (Figure 2a) could affect the outcome of
TRAIL and/or LY30 treatment. Overexpression of Hsp27
significantly rescued cells treated with LY30 and TRAIL
(Z20 ng/ml) for 16 h as compared with control cells (Figures
2b and c). Inversely, knockdown of Hsp27 expression by
siRNAs sensitized cells exposed to the combined treatment,
with a 20% difference for all doses of TRAIL used as
compared with mock transfected cells (Figure 2d). Although
silencing Hsp27 did not sensitize HeLa cells when
TRAIL was used alone, even at the highest concentration
Figure 2 Effect of Hsp27 expression modulation. (a) Western blot analysis of non transfected Hela cells, cells transiently overexpressing Hsp27 or cells where Hsp27 has
been knocked down. The indicated durations represent the time after transfection. (b) Crystal violet viability assay of HeLa cells after 16 h treatment with TRAIL (0–250 ng/ml)
in the presence or absence of 25mM LY30 in non transfected cells, (c) in cells transiently overexpressing Hsp27 or (d) in cells where Hsp27 has been knocked down.
(e) Crystal violet viability assay of HeLa cells transfected with negative siRNA or specific for Hsp27 and treated with TRAIL (0–250 ng/ml) for 24, 48 and 72 h. (f) Colony
formation assay in cells transfected with negative siRNA or specific for Hsp27 and treated with 20 ng/ml TRAIL. Colony count and colony size are provided
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(250 ng/ml), long-term survival and colony-forming experi-
ments showed a decreased cell viability/colony-forming
ability (Figures 2e and f). The decrease in cell viability was
dependent on the dose of TRAIL (Figure 2e). In addition, the
decrease in colony-forming ability was accompanied by a
significant decrease in colony size as compared with the
control.
These results suggest that Hsp27 has a role in LY30-
mediated sensitization of HeLa cells to TRAIL-induced
apoptosis as well as a role in TRAIL resistance in our cell
system, although the involvement of Hsp27 in TRAIL
resistance is only visible in medium- and long-term survival
assays.
Hsp27 localization, but not its expression, changes
upon exposure to LY30. After determining that Hsp27
had a part in TRAIL resistance and could also negatively
influence LY30 resensitization, we decided to investigate
whether LY30 also had an effect on Hsp27 expression as
previously reported by other groups for LY29 and querce-
tin.20–23 Results show that LY30 treatment, alone or in
combination with TRAIL, induced a decrease in Hsp27
protein levels in cleared RIPA lysates as evidenced by
western blot analysis (Figure 3a). However, no change could
be observed in Hsp70 or Hsp90 protein levels, suggesting
that LY30 had an effect primarily on Hsp27. We further
investigated this reduction in Hsp27 protein level upon LY30
treatment by examining Hsp27 mRNA expression as well as
the effect of the inhibition of proteasomal degradation.
Interestingly, no decrease in Hsp27 total RNA could be
detected at any of the time points tested (Figure 3b),
indicating that LY30-mediated decrease in Hsp27 expression
was not a function of its transcriptional regulation. Surpris-
ingly, pretreatment with the proteasomal inhibitor lactacystin
had no effect on Hsp27 decrease upon LY30 treatment
(Figure 3c). Taken together, these results indicate that the
decrease in Hsp27 protein level observed upon LY30
treatment was neither due to transcriptional regulation of
Hsp27 nor due to an increase in Hsp27 protein degradation.
Interestingly, Hsp27 is known to translocate to the nucleus
upon certain cellular stresses. We suspected that the cell lysis
method used (i.e., lysis with RIPA buffer followed by clearing
with centrifugation) did not provide complete lysis of the cells
and nuclei and could lead to the loss of a significant fraction of
total Hsp27 protein during the clearing step. Indeed, analysis
of the nuclei-enriched pellet obtained after sample clearing
showed an increase in the Hsp27 protein level mirroring the
decrease observed in the supernatant (Figure 3d). The lack of
such changes in whole-cell lysates or the supernatant and
pellet fractions of sonicated samples (Figures 3e and f)
confirmed the incomplete lysis hypothesis and indicated that
LY30 had no effect on Hsp27 expression but instead
induced its translocation to a nuclei-enriched pellet fraction
(Figures 3e and f).
Sustained Hsp27 nuclear translocation during LY30
treatment. In order to ascertain that Hsp27 was translo-
cated to the nucleus, we set out to monitor the presence of
Hsp27 in cytosolic and nuclear fractions obtained by using
classical cellular fractionation methods. As seen in figure 4a,
Hsp27 protein level decreases in the cytosolic fraction after
treatment with LY30, alone or in combination with TRAIL, but
concomitantly increases in the nuclei-enriched fraction as
early as 4 h, hence confirming previous results. A gentler
Figure 3 Changes in Hsp27 localization but not expression upon exposure to LY30. (a) Western blot analyses of Hsp27, Hsp70 and Hsp90 after 20 h of treatment with
LY30. (b) Total mRNA levels of Hsp27 in HeLa cells after treatment for different durations. (c) Western blot analysis of Hsp27 levels after 16 h of treatment in the presence or
absence of 10mM lactacystin (2 h preincubation). (d) Western blot analysis of Hsp27 in the pellet and supernatant fractions of cleared (centrifuged) cell lysates after 6 or 16 h of
treatment, (e) in whole-cell lysates after 4, 8 or 20 h of treatment or (f) in the pellet and supernatant fractions of sonicated cell lysates after 16 h of treatment
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nuclear fractionation method was used to monitor Hsp27
localization at the16 h time point, as the previous method was
not suited when nuclei are damaged. We observed the same
trend as for earlier time points. These results were confirmed
by immunofluorescence analysis at 4, 8 and 16 h showing a
time-dependent increase in nuclear staining in cells treated
with LY30 confirming that Hsp27 does indeed specifically
translocate to the nucleus after treatment with LY30
(Figure 4b and Supplementary Figure 3). It is important to
note that Hsp27 translocation is gradual and sustained (up to
16 h), which is in sharp contrast with the rapid and transient
nuclear translocation observed during a heat shock
(Supplementary Figure 4).
Hsp27 phosphorylation is sustained through activation
of p38/MK2 and inhibition of PP2A. After confirming that
LY30 could induce Hsp27 translocation to the nucleus, we
set out to investigate the mechanisms involved in this
translocation. Even though the precise mechanism by which
Hsp27 enters or leaves the nucleus is still unknown, it is
commonly accepted that it occurs via passive transport
through the nuclear pores. Therefore, the size of Hsp27
oligomers has to be small enough in order to permit entry into
the nucleus. As Hsp27 oligomerization is dependent on its
phosphorylation, we set out to analyze the phosphorylation
status of Hsp27 upon treatment with LY30 and TRAIL.
A marked increase in phosphorylation of Hsp27 on Ser-82
residue was observed as early as 15 min after exposure to
LY30 (Figure 5a) and was sustained for up to 16 h
(Supplementary Figure 5, Figures 5b–d). Of note, TRAIL
alone did not induce Hsp27 phosphorylation (Figure 5b).
Hsp27 is phosphorylated by MAPKAPK2 (MK2), which is
itself phosphorylated by p38 MAPK. Interestingly, both p38
and MK2 were activated upon LY30 treatment and
pretreatment with SB203580 (a specific p38 inhibitor)
abrogated the phosphorylation of p38, MK2 and Hsp27
(Figures 5a–c). Hsp27 phosphorylation can also be
regulated by PP2A. Indeed, pretreatment with okadaic acid
resulted in increased phosphorylation of Hsp27 (Figure 5d),
which suggested an effect of LY30 on PP2A. Indeed,
Figure 4 Hsp27 translocates to the nucleus. (a) Western blot analysis of Hsp27 in the nuclear and cytosolic fractions of HeLa cells following 4, 8 or 16 h exposure to 25 mM
LY30 and/or 20 ng/ml TRAIL. (b) Immunofluorescence analysis of Hsp27 cellular localization (red: Hsp27). # denotes a representative cytoplasmic localization of Hsp27,
whereas * denotes a representative nuclear localization of Hsp27. Scale bar: 10 mm
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a significant inhibition of PP2A activity could be observed
upon treatment with LY30 alone as early as 1 h (Figure 5e).
Interestingly, an even stronger inhibition was observed
after 6 h in samples treated with LY30, whereas no additive
effect could be observed with the combined treatment.
Taken together, these results indicate that LY30 is able to
induce Hsp27 phosphorylation by activating p38 MAKP as
well as inhibiting PP2A.
LY30 induces a shift in Hsp27 oligomeric size toward
small oligomers. Having established the ability of LY30 to
modulate Hsp27 phosphorylation status, we set out to
investigate the subsequent effect on Hsp27 oligomerization.
To that end, we performed glycerol gradient ultracentrifuga-
tion. In untreated cells, Hsp27 sedimented as complexes of
heterogeneous sizes distributed between the top of the
gradient (monomers, dimers and low-molecular size oligo-
mers) and fractions corresponding to a high-molecular
masses (Figures 6a and b). Interestingly, 1 h treatment with
LY30 resulted in a drastic change in the size distribution of
Hsp27 oligomers with a shift toward the lower molecular size
oligomers. A longer exposure to LY30, alone or in combina-
tion with TRAIL, led to a similar shift toward small oligomers.
To confirm these results, glutaraldehyde cross-linking experi-
ments were performed (Figure 6c). Hsp27 cross-linking was
markedly reduced in LY30-treated samples, in particular the
higher size cross-linked products. Moreover, treatment with
okadaic acid, which is able to increase Hsp27 phosphoryla-
tion, induced a comparable shift. Inversely, pretreatment with
the p38 MAPK inhibitor SB203580 abrogated LY30-mediated
shift in Hsp27 oligomeric size (Figure 6a).
These results suggest that modulation of Hsp27 phosphor-
ylation by LY30 directly influences the equilibrium between
high- and low-molecular size Hsp27 oligomers in favor of the
latter.
Hsp27 chaperone activity is inhibited by LY30. The
capacity of Hsp27 to protect proteins from denaturation is
proposed to be in part responsible for its anti-apoptotic
activity. Hsp27 chaperone activity has been associated with
the fraction of Hsp27 oligomers displaying high-molecular
masses. On the basis of the effect of LY30 on Hsp27
oligomerization, we next asked whether LY30 had an effect
on Hsp27 chaperone activity.
HeLa cells transiently expressing the renilla luciferase
gene were treated as described in the experimental setup
outlined in Supplementary Figure 5. As this assay measures
the overall chaperone activity in the cell (i.e., the activity of all
chaperone proteins), both specific overexpression and
silencing of Hsp27 were used to determine the contribution
of Hsp27 in the overall chaperone activity (Figure 7a). As
seen in figure 7b, the heat shock was sufficient to denature
luciferase efficiently (HSR0 þ / LY) and a 3 h recovery
period was enough to observe a significant renaturation of
the protein. Interestingly, Hsp27 overexpression was able to
enhance protein renaturation by about 140%, whereas
Hsp27 silencing reduced it by 40% as compared with the
control (Figure 7b), indicating that Hsp27 accounted for a
significant part of the chaperone activity in the cell. More
importantly, results show that LY30 treatment significantly
reduced Hsp27 chaperone activity both in control and in
Hsp27 overexpressing cells.
Figure 5 Sustained Hsp27 phosphorylation. (a) Western blot analysis of total Hsp27, phospho-Hsp27 and MK2 after treatment with 25mM LY30 for the indicated times or
(b) treated for 6 or 16 h with 20 ng/ml TRAIL with or without preincubation with 25mM LY30. (c) Western blot analysis of total Hsp27, phospho-Hsp27, phospho-p38, MK2 and
phospho-MK2 after 16 h in the presence or absence of 10 mM SB203580. (d) Western blot analysis of total Hsp27, phospho-Hsp27 after 16 h treatment in the presence or
absence of 10mM okadaic acid. (e) PP2A phosphatase activity following the indicated treatments (OA: okadaic acid) *Po0.01
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Taken together these results show that LY30 is able to
induce profound biochemical changes to Hsp27 protein,
thereby impairing its protective functions and relieving the
breaks on apoptosis.
Discussion
In this study, we report a novel mechanism by which LY30
sensitizes tumor cells to TRAIL-mediated cell death that
involves the alteration of Hsp27 protective functions. Our
results show that, although Hsp27 expression remained
unchanged upon exposure to LY30, its cellular localization
was drastically changed. Indeed, we observed slow and
sustained translocation of Hsp27 to the nucleus. Such
translocation of Hsp27 has been extensively described
in the literature in response to different type of cellular
stress24–26 and is usually rapid and transient. It is thought that
such translocation allows Hsp27 to exert its protective
functions in the nucleus for the duration of the cellular stress
by sequestration of critical components of the translational
and transcriptional machinery in order to prevent them to be
damaged,27 and thus allows for a faster recovery upon return
to physiological conditions. However, a sustained nuclear
translocation of Hsp27 can be viewed as a nuclear seques-
tration of the protein. Indeed, the continual decrease in the
cytosolic pool of Hsp27 is very likely to diminish the protection
offered by this protein in the cytosol and might very well lead to
a more efficient activation of caspases, in particular caspase-
3 and caspase-9.
As Hsp27 does not contain a nuclear localization signal, its
transport to and from the nucleus is thought to be passive,
through the nuclear pores, implying a small enough protein
complex. In that regard, a study using Hsp27 fused to GFP
reported that in some cell lines the fused protein was unable to
enter the nucleus,28 indicating that Hsp27 needs to be in its
monomeric or dimeric form in order to enter the nucleus.
Hsp27 is present in the cell in the oligomeric form and
oligomers of varying sizes are in a dynamic equilibrium
regulated by Hsp27 phosphorylation. Hsp27 has been shown
to be phosphorylated following exposure to several cellular
stresses and drugs.29–35 Here, we show that Hsp27 was
rapidly phosphorylated upon exposure to LY30 and that,
unlike other reports its phosphorylation was sustained for up
to 16 h, which seems to indicate a constant upstream
regulation. Stress-induced phosphorylation of Hsp27 is
catalyzed mainly by p38 MAPK cascade and leads to the
Figure 6 Effect of LY30 on Hsp27 oligomers size distribution. (a) HeLa cells were treated with 25mM LY30 for 1 h in the presence or absence of 10mM SB203580 or
10mM okadaic acid (OA) (2 h preincubation) or (b) treated for 6 h with 20 ng/ml TRAIL with or without preincubation with 25 mM LY30. The cell extracts were fractionated by
centrifugation on glycerol gradient. Each fraction was slot-blotted and Hsp27 was detected by immunoblotting using anti-HSP27. Immunoblots were then analyzed by
densitometry. (c) Glutaraldehyde cross-linking of cell lysates from cells treated for 1 h with 20 ng/ml TRAIL with or without preincubation with 25 mM LY30
Figure 7 Effect of LY30 on in vivo chaperone activity. In vivo chaperone activity.
A schematic experimental setup is provided in Supplementary Figure 5. *Po0.05.
HSR0: no recovery after heat-shock, HSR180: 3 h recovery after heat-shock
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activation of MK2, a major kinase involved in Hsp27
phosphorylation.36–38 Indeed LY30 induced a rapid activation
of p38 and MK2 and inhibition of p38 led to a marked decrease
in MK2 and Hsp27 phosphorylation.
Hsp27 phosphorylation is also regulated by PP2A activ-
ity.39,40 We first confirmed that PP2A was functional and could
affect Hsp27 phosphorylation before showing that PP2A was
inhibited following exposure to LY30. A small, but significant,
inhibition of PP2A (25% inhibition) after 1 h of preincubation
with LY30 suggests that Hsp27 rapid phosphorylation is likely
mediated by rapid p38/MK2 activation rather than fast
inhibition of PP2A. The strong inhibition observed after 6 h
of treatment (60%) helps to explain the sustained phosphor-
ylation of Hsp27. How LY30 activates p38 and inhibits PP2A
remains to be answered. However, both p38 and PP2A have
been shown to be sensitive to ROS,41–43 which is produced
upon exposure to LY30 and can lead to p38 activation as
shown by Shenoy et al.12 Moreover, PP2A can negatively
regulate p38 and MK2.44,45 Hence, inhibition of PP2A by LY30
would enhance Hsp27 phosphorylation directly and/or indirectly.
Interestingly, two studies by Song’s et al.46,47 have recently
shown that increased phosphorylation of Hsp27 and p38 was
responsible for tilting the cell fate toward apoptosis during
curcumin and TRAIL treatment via modulation of Akt survival
pathway, hence strengthening our hypothesis that increased
Hsp27 phosphorylation is important for TRAIL sensitization.
Having shown that LY30 induced changes in Hsp27
phosphorylation, we investigated the potential effects on
Hsp27 oligomeric conformation. Corroborating earlier find-
ings, we confirmed the existence of two distinct populations of
oligomers in HeLa cells.48,49 The addition of LY30 induced a
drastic and very rapid shift in Hsp27 oligomeric size in favor of
the smaller oligomers. Furthermore, inhibition of PP2A led to a
similar shift, whereas inhibition of p38 blocked the LY30-
mediated shift, thus providing a clear link between LY30-
mediated phosphorylation of Hsp27 and Hsp27 large oligo-
mers dissociation. On a side note, LY30 did not lead to a
complete and transient dissociation of Hsp27 oligomers into
monomers and dimers, but rather to a mixture of small
oligomers of varying sizes along with monomers and dimers,
the composition of this mixture being sustained during the
treatment. This might explain why the observed nuclear
translocation of Hsp27 was slow and sustained rather that
massive and transient.
Large Hsp27 oligomers provide Hsp27 with its chaperone
activity.49 Interestingly, the overall activity is decreased by
40% when Hsp27 is silenced, whereas overexpression
markedly enhances it (35% increase). This indicates that
Hsp27 is a major component of the chaperone machinery in
HeLa cells. LY30 affects the overall chaperone activity in the
cells and inhibits it by 40%. Interestingly, even though the
chaperone activity is enhanced in cells overexpressing
Hsp27, LY30 leads to an inhibition comparable to that in
control cells, which is indicative of a specific effect of LY30
toward Hsp27, independently of Hsp27 protein level. The
inhibition of Hsp27 chaperone activity likely leaves the cells
exposed to potentially toxic aggregates of denatured proteins.
Interestingly, Hsp27 large oligomers not only serve to create
large reservoir of misfolded proteins awaiting to be refolded or
degraded but can also sequester functional, non-denatured
proteins. On one hand, Hsp27 large oligomers have been
shown to be responsible for the protection of key enzymes of
the redox system,49,50 thereby favoring the formation of
reduced glutathione and hence keeping ROS levels low.
Thus, the dissociation of large oligomers observed following
treatment with LY30 is likely to negate the beneficial effect of
Hsp27 on cellular redox status. Moreover, the rapidity at which
the large oligomers disappear (within 1 h) could actually
maximize the damage brought about by the early LY30-
mediated ROS burst. On the other hand, large oligomers have
been demonstrated to be the active form for the general
caspase-dependent anti-apoptotic effect of Hsp27.48 Like-
wise, this protective function could be greatly diminished as
the large oligomeric population decreases.
Finally, the modulation of Hsp27 expression showed that
Hsp27 represents an important apoptotic block in our cell
system and that it not only has a significant role in LY30
sensitization to TRAIL but also in TRAIL resistance. These
results are in line with findings from a recent study by Zhuang
et al.51 showing that downregulation of Hsp27 could sensitize
cells to TRAIL-induced apoptosis. Hence, the targeting of
Hsp27, a protein with multiple protective roles, by LY30
translates into the weakening of tumor cells defenses and, in
association with its other effects on TRAIL apical signaling,
permits the generation and efficient transduction of an
apoptotic signal.
Conclusion
In conclusion, we describe a novel mechanism where LY30
restores tumor cells sensitivity to TRAIL treatment by priming
the cells via inhibition of Hsp27 protective function. This
mechanism involves a sustained phosphorylation of Hsp27,
through activation of the p38/MK2 pathway and the inhibition
of PP2A, which in turn results in Hsp27 nuclear sequestration
and inhibition of its chaperone activity due the loss of high-
molecular weight Hsp27 oligomers. This study demonstrates
the importance of targeting Hsp27 in order to alleviate TRAIL
resistance in cancer cells and, taken together with our
previous reports, describe LY30 as a truly pleiotropic small
molecule with a strong potential to help build a better
understanding on how to overcome drug resistance in cancer.
Materials and Methods
Reagents. The plasmid pcDNA-Hsp27 containing the full-length human hsp27
gene was a generous gift from Doctor Borelli (Department of Radiation Oncology,
University of Arkansas Medical School, Little Rock, AR, USA). The pcDNA3.1þ
vector was obtained from Invitrogen (Carlsbad, CA, USA). siRNAs for Hsp27 and
the negative control siRNA were obtained from Dharmacon (Lafayette, CO, USA).
Human recombinant TRAIL was purchased from Biomol International
(Farmingdale, NY, USA), LY303511 from Alexis. Lactacystin, SB203580 and
okadaic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell line and culture conditions. The human cervical cancer cell line
HeLa was purchased from American Type Culture Collection (ATCC, Manassas,
VA, USA). HeLa cells were cultured in Dulbecco’s Modified Eagle’s medium
(Hyclone, Waltham, MA, USA) supplemented with 1% L-glutamine, 1%
streptomycin-penicillin and 10% FBS (Gibco, Carlsbad, CA, USA).
Determination of cell viability and clonogenic growth. HeLa cells
were treated as indicated and cell viability was assessed by the crystal violet
staining method and trypan blue exclusion assay, whereas clonogenic growth was
determined by crystal violet staining after 10–14 days of culture.
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Western blot analysis. Western blot analysis were performed as previously
described12 using antibodies against Hsp27 (Assay Designs/Stressgen,
Farmingdale, NY, USA), phospho-Hsp27 (ser82), Hsp70, Hsp90, PARP, Smac
(BD Pharmingen, San Jose, CA, USA), Actin, MAPKAP kinase 2 (MK2) (Cell
Signaling Technology, Danvers, MA, USA), phospho-p38 (T180/Y182). Secondary
antibodies conjugated to horseradish peroxidase (Pierce Biotechnology, Rockford,
IL, USA) were used for detection and followed by enhanced chemiluminescence
(Pierce Biotechnology) and autoradiography.
Densitometry. Densitometry measurements were done using the image
analysis software Image J (http://rsbweb.nih.gov/ij/). When necessary, normal-
ization was done against the loading control (actin).
DNA and siRNA transfections. For transient expression, HeLa cells
(106 cells per 100 mm) were transfected with 10 mg of pcDNA-Hsp27 or
pcDNA3.1þ using the calcium phosphate transfection method. For knockdown of
gene expression, 50 nM siRNA (Hsp27 siRNA or negative control siRNA) was
transfected according to the protocol provided by the manufacturer (Dharmacon).
In each case, cells were cultured for 24 h before trypsinization and seeding for
subsequent experiments.
PP2A activity assay. Following treatment, HeLa cells were lysed in a buffer
containing 1 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4) and 1% Triton
X-100, supplemented with proteases inhibitors. The cell lysates were then
sonicated and centrifuged for 15 min at 16000 g. PP2A activity in the
supernatants was assayed according to the protocol provided by the manufacturer
using (phosphatase kit V2460, Promega, Madison, WI, USA).
Cellular fractionation
Soluble/insoluble fractions: RIPA cell lysates were incubated on ice for
15 min with intermittent vortexing and freeze/thawed twice with another round of
vortexing in-between. The lysates were then centrifuged at 16 000 g for 15 min.
The supernatant was kept and the pellet was resuspended in 1 RIPA buffer.
Nuclear fractionation (4 and 8h treatment): Following treatment, HeLa
cells were harvested in PBS and nuclear fraction was performed as described by
Cok et al.52
Alternative nuclear fractionation (16 h treatment): Cells were resus-
pended in 400 ml of buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 100 mM EDTA,
100 mM EGTA) and incubated on ice for 15 min. Then, 25 ml of NP-40 was added
to the cell suspension followed by vigorous vortexing for 10 s. The cell suspension
was then centrifuged at 16000 g for 30 s at 4 1C. The supernatant (cytosolic
fraction) was stored at  80 1C. The pellet (nuclear fraction) was resuspended in
50ml of ice-cold buffer C (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA,
1 mM EGTA) and incubated for 15 min at 4 1C before storage at  80 1C.
Immunofluorescence analysis. Cells were fixed by adding 4% formalde-
hyde and quenched with 100 mM glycine. 2% dodecyltrimethylammonium chloride
was added to permeabilize the membrane and 50 mM NH4Cl2 to remove auto-
fluorescence, before blocking with 5% BSA. Cells were probed with polyclonal rabbit
anti-Hsp27 (Santa Cruz Biotechnology, Dallas, TX, USA). Immune complex formation
was detected using an Alexa Fluor 568-conjugated secondary antibody (Molecular
Probes/Invitrogen, Eugene, OR, USA). Nuclei were stained with Hoechst-33342
(Molecular Probes/Invitrogen). Pictures were taken with an Olympus BX53
microscope ( 40 magnification lens) and an Olympus DP72 camera. Olympus
software cellSens Dimension was used to save and merge the images.
Hsp27 oligomerization analysis. The glycerol gradient centrifugation and
the glutaraldehyde protocols were adapted from Lambert et al.53 and performed
using HeLa cells.
In vivo chaperone activity assay. The in vivo chaperone activity assay
was adapted from Nollen et al.54 A schematic of the experimental setup is
provided in the Supplementary Data section (Supplementary Figure 6).
Statistical analysis. All experiments were performed at least three times for
statistical significance. Numerical data were expressed as mean±S.D. Statistical
analysis was performed using the paired Student’s t-test considering the variances
unequal. P-valueso0.05 were considered significant.
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